CLINICAL & PIPELINE·Drug Approval
Incyte's Minjuvi (Tafasitamab) Secures MHLW Approval for Relapsed/Refractory DLBCL in Japan, Reshaping Oncology Supply Chains
Incyte's Minjuvi (tafasitamab) + lenalidomide received MHLW approval for relapsed/refractory DLBCL in Japan. This introduces a critical new biologic (HSN: 30049099) for patients ineligible for autologous stem cell transplant, creating significant implications for procurement, regulatory affairs, and supply chain strategies within the Japanese oncology market for Incyte and its partners.
90-Day Activity